Project Details
Description
Abstract
This multi-site study aims to establish best practice recommendations and clinical value of a new consensus
protocol for dynamic susceptibility contrast (DSC) MRI. DSC-MRI is one of the most widely used physiologic
imaging techniques in neuro-oncology, with a reported use in 85% of all routine brain tumor scans at sites across
the US and Europe. DSC-MRI measures of relative cerebral blood volume (rCBV) can differentiate glioma
grades, identify tumor components in non-enhancing glioma, distinguish tumor recurrence from post-treatment
effects (including pseudoprogression and radiation necrosis) and predict treatment response and patient survival
after targeted therapy. Despite this demonstrated value, translation of consistent clinical DSC-MRI guidelines
across multiple institutions remains challenging owing to variability in acquisition and post-processing protocols.
To improve the accuracy, repeatability, and multi-site consistency of DSC-MRI, the team of investigators on this
proposal identified and validated a DSC-MRI protocol that has since become a consensus recommendation for
patients with glioma. Accordingly, we are well positioned to address critical gaps in this field that, once solved,
will accelerate the widespread adoption of the consensus protocol and direct its use in clinical practice. We first
aim to establish best practices for the pre- and post-processing methods for DSC-MRI. We will then leverage
our expertise with image-localized biopsies and matched image-tissue correlations to establish guidelines for
interpreting rCBV maps generated with the consensus protocol, specifically applied to the differentiation of low-
from high-grade glioma, and progression of high-grade glioma from post-treatment effects. Finally, we aim to
establish the clinical value added of the consensus DSC-MRI protocol for impacting brain tumor patient
management. These studies will address key practical and clinical unmet needs that will directly facilitate the
future use of DSC-MRI in glioma patients, thereby promoting widespread adoption of the consensus DSC-MRI
protocol.
Status | Finished |
---|---|
Effective start/end date | 3/1/22 → 2/29/24 |
Funding
- National Cancer Institute: $765,016.00
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.